Skip to content

Effect of iodine group of medicine on persons suffering from allergic rhinitis with increased IgE level.

Effect of the drugs of Iodine group on increased IgE related clinical manifestations of Allergic Rhinitis: An Open Label, Prospective Study - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/06/088728
Enrollment
45
Registered
2025-06-12
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J069- Acute upper respiratory infection,unspecified

Interventions

Intervention1: Administering of the drugs of iodine group to patients diagnosed with allergic rhinitis and elevated serum IgE levels.: The intervention involves administering of the drugs of iodine gr

Sponsors

The Calcutta Homoeopathic Medical College and hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients aged between 6 years and 65 years. 2.Diagnosed with allergic rhinitis based on clinical presentation and confirmed by elevated serum IgE levels above 200 IU per ml. 3.Patients having characteristic symptoms of drugs of iodine group. 4.Baseline Total Nasal Symptom Score (TNSS) more than 4. 5.Patients who have not been treated with any method of treatment in the last 6 weeks.

Exclusion criteria

Exclusion criteria: 1.Patients with other comorbid respiratory diseases such as asthma or chronic obstructive pulmonary disease (COPD). 2.Patients who have lack of characteristic symptoms of drugs of iodine group. 3.Unstable mental or psychiatric illness or other systemic diseases (e.g., uncontrolled hypertension, diabetes, thyroid diseases etc.) affecting quality of life or any vital organ failure 4.Any substance abuses 5.Self-reported immune-compromised state 6.Pregnant and puerperal women, and lactating mothers. 7.Simultaneous participation of any other clinical trials. 8. Undergoing homoeopathic treatment within last 6 weeks.

Design outcomes

Primary

MeasureTime frame
1. Serum IgE 2. Total Nasal Symptom Score (TNSS)Timepoint: 1. At baseline and after 3rd and 6th months. 2. every months upto 6 months.

Secondary

MeasureTime frame
Rhino conjunctivitis Quality of Life Questionnaire (RQLQ)Timepoint: every months upto 6months

Countries

India

Contacts

Public ContactDr Somnath Paul

The Calcutta Homoeopathic Medical College and hospital

drkisorkumarnaskar@gmail.com9433039891

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026